Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: email@example.com
F-627 Shows Strong, Beneficial for Chemotherapy-Induced Neutropenia in Breast CancerJuly 11th 2020
Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.
FDA Issues Clinical Hold on CAR-T Cell Trial for Patients With MyelomaJuly 8th 2020
The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma, according to Cellectis, the manufacturer of the product.
FDA Approval Sought for Pralsetinib to Treat Advanced RET+ Thyroid CancersJuly 2nd 2020
A new drug application (NDA) has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion–positive thyroid cancers, according to an announcement from Blueprint Medicines, the developer of the drug.
FDA Approves Frontline Pembrolizumab for MSI-H/dMMR Metastatic CRCJune 30th 2020
The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer. This marks the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy.
FDA Grants Naxitamab Priority Review for High-Risk NeuroblastomaJune 4th 2020
The FDA has granted a priority review designation to a biologics license application (BLA) for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Ruxolitinib Discontinuation Worsens Myelofibrosis Outcomes, Highlighting Unmet NeedMay 26th 2020
A United States population-based outcome analysis of real-world patients with myelofibrosis who had discontinued ruxolitinib (Jakafi) demonstrated an increase in morbidity burden and identified the risk factors of survival outcomes, according to John O. Mascarenhas, MD.
Oncology Clinicians Must Be Adaptable in COVID-19 PandemicApril 19th 2020
Just as the situation with COVID-19 continues to rapidly evolve, the oncology community must actively adapt how they approach the treatment of their patients based on the information available, according to Balazs Halmos, MD, MS.
COVID-19 Pandemic Interrupts Cancer CareMarch 28th 2020
To hinder the rapid spread of COVID-19 across the globe, mandatory lockdowns have been put into place to encourage the practice of social distancing, explained Omid Hamid, MD; however, efforts to prevent close contact, and thus exposure to the virus, have also caused disruptions in access to care for patients with cancer.
Surgery Refinements Named ASCO's Advance of the YearFebruary 9th 2020
Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.
Unmet Needs Remain in TNBC TreatmentFebruary 3rd 2020
Despite the emergence of PARP inhibitors, antibody-drug conjugates (ADCs), and immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC), more work is needed to propel further progress, according to Kevin Kalinsky, MD, MS.
Breast Cancer Outcomes Can Be Predicted by Residual Cancer BurdenDecember 16th 2019
Residual cancer burden (RCB) after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes, according to data from a large meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium.
Immunotherapy Combo Is Promising in MSI-H Colorectal CancerAugust 26th 2019
The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer (mCRC) whose tumors are microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR)—a population with a historically poor prognosis, said Heinz-Josef Lenz, MD, FACP.
FDA Approves Prefilled Syringe for GEP-NETs TreatmentJune 25th 2019
The FDA has granted an approval to a prefilled syringe for lanreotide (Somatuline Depot), which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
Expert Looks Ahead in Prostate Cancer TreatmentMay 12th 2019
When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.